bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, announced that unit sales for its CyPath® Lung diagnostic in the first quarter of 2026 exceeded internal projections, achieving a remarkable 146% growth compared to the first quarter of 2025. This surge in sales reflects accelerating physician adoption and expanding clinical use of the company’s noninvasive lung cancer diagnostic test. The growth is particularly significant given the current and expanding U.S. addressable market for pulmonary nodule management and surveillance of lung cancer survivors, which is estimated at $3.58 billion. The company’s innovative flow cytometry combined with artificial intelligence technology is designed to improve lung cancer risk assessment and nodule management, addressing a critical gap in the diagnostic pathway. Maria Zannes, President and CEO of bioAffinity Technologies, stated, "The stronger than expected unit growth in the first quarter of 2026 reflects growing recognition of the value that CyPath® Lung brings to clinical decision-making and patient outcomes. Physicians are seeking more accurate, noninvasive tools to assess lung cancer risk and detect disease at its earliest, most treatable stage. Our growing body of evidence, including real-world case studies, further supports CyPath® Lung’s potential clinical utility." The company is also advancing multiple initiatives to expand the clinical impact of its proprietary technology platform, including a large-scale longitudinal clinical study and broader use of CyPath® Lung to monitor lung cancer survivors after treatment. With these developments, bioAffinity Technologies is well-positioned for continued growth in the diagnostic market.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.